Precision Pioneers EP 5: Alnylam's Josh Friedman on developing precision medicines for the 'silent killer' NASH/NAFLD

Om avsnittet

On this episode of the podcast, Patrick is joined by Josh Friedman, Senior Director of Research at Alnylam Pharmaceuticals. Alnylam works on the discovery and development of RNA interference therapeutics; treatments for genetic diseases which work by ‘switching off’ the specific genes associated with a given condition. In this fifth episode of our precision pioneers miniseries, we explore how RNA interference can be applied to treat common and rare genetic diseases, and dive deep into the genetics of non-alcoholic fatty liver disease and NASH.

Om avsnittet

Fler avsnitt

EP 257: Managing hereditary cancer risk and medical uncertainty with Marleah Dean Kruzel of the University of South Florida

EP 256: Cutting through the AI hype in drug discovery with Dave Hallett of Recursion

EP 255: Turning long-read sequencing into a routine part of clinical care with Danny Miller of the University of Washington

EP 254: Triangulating genetic evidence and dodging bias to pick winning drug targets with Brent Richards of 5 Prime Sciences

EP 253: The genetics of brain size, growth, and aging with Andrew Jackson of the University of Edinburgh

EP 252: The diagnosis that became a mission to cure rare disease: Advancing genetic medicine using AI with Stevie Ringel of Nome

EP 251: Cracking the delivery barrier in genetic medicine with Jagesh Shah of Mirai Bio

EP 250: Redefining rare disease realities with Sharon Terry of the Genetic Alliance [Re-run]

EP 249: Building the world's most detailed genetic map of inflammatory bowel disease with Carl Anderson of the Wellcome Sanger Institute

EP 248: The blood mutations rewriting cardiovascular risk: Clonal hematopoiesis and polygenic risk with Pradeep Natarajan of Massachusetts General Hospital